Yiling Lu, M.D.

Peer-Reviewed Articles

1. Ghandi M, Huang FW, Jané-Valbuena J, Kryukov GV, Lo CC, McDonald ER, Barretina J, Gelfand ET, Bielski CM, Li H, Hu K, Andreev-Drakhlin AY, Kim J, Hess JM, Haas BJ, Aguet F, Weir BA, Rothberg MV, Paolella BR, Lawrence MS, Akbani R, Lu Y, Tiv HL, Gokhale PC, de Weck A, Mansour AA, Oh C, Shih J, Hadi K, Rosen Y, Bistline J, Venkatesan K, Reddy A, Sonkin D, Liu M, Lehar J, Korn JM, Porter DA, Jones MD, Golji J, Caponigro G, Taylor JE, Dunning CM, Creech AL, Warren AC, McFarland JM, Zamanighomi M, Kauffmann A, Stransky N, Imielinski M, Maruvka YE, Cherniack AD, Tsherniak A, Vazquez F, Jaffe JD, Lane AA, Weinstock DM, Johannessen CM, Morrissey MP, Stegmeier F, Schlegel R, Hahn WC, Getz G, Mills GB, Boehm JS, Golub TR, Garraway LA, Sellers WR. Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature 569(7757):503-508, 2019. e-Pub 2019. PMID: 31068700.
2. Li X, Mak VCY, Zhou Y, Wang C, Wong ESY, Sharma R, Lu Y, Cheung ANY, Mills GB, Cheung LWT. Deregulated Gab2 phosphorylation mediates aberrant AKT and STAT3 signaling upon PIK3R1 loss in ovarian cancer. Nat Commun 10(1):716, 2019. e-Pub 2019. PMID: 30755611.
3. Hmeljak J, Sanchez-Vega F, Hoadley KA, Shih J, Stewart C, Heiman D, Tarpey P, Danilova L, Drill E, Gibb EA, Bowlby R, Kanchi R, Osmanbeyoglu HU, Sekido Y, Takeshita J, Newton Y, Graim K, Gupta M, Gay CM, Diao L, Gibbs DL, Thorsson V, Iype L, Kantheti H, Severson DT, Ravegnini G, Desmeules P, Jungbluth AA, Travis WD, Dacic S, Chirieac LR, Galateau-Sallé F, Fujimoto J, Husain AN, Silveira HC, Rusch VW, Rintoul RC, Pass H, Kindler H, Zauderer MG, Kwiatkowski DJ, Bueno R, Tsao AS, Creaney J, Lichtenberg T, Leraas K, Bowen J, TCGA Research Network [Lu Y], Felau I, Zenklusen JC, Akbani R, Cherniack AD, Byers LA, Noble MS, Fletcher JA, Robertson AG, Shen R, Aburatani H, Robinson BW, Campbell P, Ladanyi M. Integrative Molecular Characterization of Malignant Pleural Mesothelioma. Cancer Discov 8(12):1548-1565, 2018. e-Pub 2018. PMID: 30322867.
4. Korkut A, Zaidi S, Kanchi RS, Rao S, Gough NR, Schultz A, Li X, Lorenzi PL, Berger AC, Robertson G, Kwong LN, Datto M, Roszik J, Ling S, Ravikumar V, Manyam G, Rao A, Shelley S, Liu Y, Ju Z, Hansel D, de Velasco G, Pennathur A, Andersen JB, O'Rourke CJ, Ohshiro K, Jogunoori W, Nguyen BN, Li S, Osmanbeyoglu HU, Ajani JA, Mani SA, Houseman A, Wiznerowicz M, Chen J, Gu S, Ma W, Zhang J, Tong P, Cherniack AD, Deng C, Resar L, Cancer Genome Atlas Research Network [Lu Y], Weinstein JN, Mishra L, Akbani R. A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF-β Superfamily. Cell Syst 7(4):422-437.e7, 2018. e-Pub 2018. PMID: 30268436.
5. Zhang G, Frederick DT, Wu L, Wei Z, Krepler C, Srinivasan S, Chae YC, Xu X, Choi H, Dimwamwa E, Ope O, Shannan B, Basu D, Zhang D, Guha M, Xiao M, Randell S, Sproesser K, Xu W, Liu J, Karakousis GC, Schuchter LM, Gangadhar TC, Amaravadi RK, Gu M, Xu C, Ghosh A, Xu W, Tian T, Zhang J, Zha S, Liu Q, Brafford P, Weeraratna A, Davies MA, Wargo JA, Avadhani NG, Lu Y, Mills GB, Altieri DC, Flaherty KT, Herlyn M. Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors. J Clin Invest 126(5):1834-1856, 2016. e-Pub 2016. PMID: 27043285.
6. Budina-Kolomets A, Webster MR, Leu JI, Jennis M, Krepler C, Guerrini A, Kossenkov AV, Xu W, Karakousis G, Schuchter L, Amaravadi RK, Wu H, Yin X, Liu Q, Lu Y, Mills GB, Xu X, George DL, Weeraratna AT, Murphy ME. HSP70 inhibition limits FAK-dependent invasion and enhances the response to melanoma treatment with BRAF inhibitors. Cancer Res 76(9):2720-30, 2016. e-Pub 2016. PMID: 26984758.
7. Krepler C, Xiao M, Sproesser K, Brafford PA, Shannan B, Beqiri M, Liu Q, Xu W, Garman B, Nathanson KL, Xu X, Karakousis GC, Mills GB, Lu Y, Ahmed TA, Poulikakos PI, Caponigro G, Boehm M, Peters M, Schuchter LM, Weeraratna AT, Herlyn M. Personalized pre-clinical trials in BRAF inhibitor resistant patient derived xenograft models identify second line combination therapies. Clin Cancer Res 22(7):1592-602, 2016. e-Pub 2015. PMID: 26673799.
8. Bissig-Choisat B, Kettlun-Leyton C, Legras XD, Zorman B, Barzi M, Chen LL, Amin MD, Huang YH, Pautler RG, Hampton OA, Prakash MM, Yang D, Borowiak M, Muzny D, Doddapaneni H, Hu J, Shi Y, Gaber WM, John Hicks M, Thompson PA, Lu Y, Mills GB, Finegold M, Goss JA, Williams Parsons D, Vasudevan SA, Sumazin P, Lopez-Terrada D, Bissig KD. Novel Patient-Derived Xenograft and Cell Line Models for Therapeutic Testing of Pediatric Liver Cancer. J Hepatol. e-Pub 2016. PMID: 27117591.
9. Chen F, Zhang Y, Senbabaoglu Y, Ciriello G, Yang L, Reznik E, Shuch B, Micevic G, De Velasco G, Shinbrot E, Noble MS, Lu Y, Covington KR, Xi L, Drummond JA, Muzny D, Kang H, Lee J, Tamboli P, Reuter V, Shelley CS, Kaipparettu BA, Bottaro DP, Godwin AK, Gibbs RA, Getz G, Kucherlapati R, Park PJ, Sander C, Henske EP, Zhou JH, Kwiatkowski DJ, Ho TH, Choueiri TK, Hsieh JJ, Akbani R, Mills GB, Hakimi AA, Wheeler DA, Creighton CJ. Multilevel Genomics-Based Taxonomy of Renal Cell Carcinoma. Cell Rep 14(10):2476-89, 2016. e-Pub 2016. PMID: 26947078.
10. Seviour EG, Sehgal V, Lu Y, Luo Z, Moss T, Zhang F, Hill SM, Liu W, Maiti SN, Cooper L, Azencot R, Lopez-Berestein G, Rodriguez-Aguayo C, Roopaimoole R, Pecot CV, Sood AK, Mukherjee S, Gray JW, Mills GB, Ram PT. Functional proteomics identifies miRNAs to target a p27/Myc/phospho-Rb signature in breast and ovarian cancer. Oncogene 35(6):801, 2016. PMID: 26865225.
11. He N, Kim N, Jeong E, Lu Y, Mills GB, Yoon S. Glucose starvation induces mutation and lineage-dependent adaptive responses in a large collection of cancer cell lines. Int J Oncol 48(1):67-72, 2016. PMID: 26573869.
12. Wang C, Zhu X, Feng W, Yu Y, Jeong K, Guo W, Lu Y, Mills GB. Verteporfin inhibits YAP function through up-regulating 14-3-3σ sequestering YAP in the cytoplasm. Am J Cancer Res 6(1):27-37, 2016. e-Pub 2015. PMID: 27073720.
13. Ceccarelli M, Barthel FP, Malta TM, Sabedot TS, Salama SR, Murray BA, Morozova O, Newton Y, Radenbaugh A, Pagnotta SM, Anjum S, Wang J, Manyam G, Zoppoli P, Ling S, Rao AA, Grifford M, Cherniack AD, Zhang H, Poisson L, Carlotti CG, Tirapelli DP, Rao A, Mikkelsen T, Lau CC, Yung WK, Rabadan R, Huse J, Brat DJ, Lehman NL, Barnholtz-Sloan JS, Zheng S, Hess K, Rao G, Meyerson M, Beroukhim R, Cooper L, Akbani R, Wrensch M, Haussler D, Aldape KD, Laird PW, Gutmann DH, TCGA Research Network [Lu Y], Noushmehr H, Iavarone A, Verhaak RG. Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma. Cell 164(3):550-63, 2016. PMID: 26824661.
14. Klionsky DJ and others, including Lu Y. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy 12(1):1-222, 2016. PMID: 26799652.
15. Roy A, Skibo J, Kalume F, Ni J, Rankin S, Lu Y, Dobyns WB, Mills GB, Zhao JJ, Baker SJ, Millen KJ. Mouse models of human PIK3CA-related brain overgrowth have acutely treatable epilepsy. Elife 4, 2015. PMID: 26633882.
16. Cancer Genome Atlas Research Network [Lu Y]. Electronic address: schultz@cbio.mskcc.org, Cancer Genome Atlas Research Network. The Molecular Taxonomy of Primary Prostate Cancer. Cell 163(4):1011-25, 2015. PMID: 26544944.
17. Linehan WM, Spellman PT, Ricketts CJ, Creighton CJ, Fei SS, Davis C, Wheeler DA, Murray BA, Schmidt L, Vocke CD, Peto M, Al Mamun AA, Shinbrot E, Sethi A, Brooks S, Rathmell WK, Brooks AN, Hoadley KA, Robertson AG, Brooks D, Bowlby R, Sadeghi S, Shen H, Weisenberger DJ, Bootwalla M, Baylin SB, Laird PW, Cherniack AD, Saksena G, Haake S, Li J, Liang H, Lu Y, Mills GB, Akbani R, Leiserson MD, Raphael BJ, Anur P, Bottaro D, Albiges L, Barnabas N, Choueiri TK, Czerniak B, Godwin AK, Hakimi AA, Ho TH, Hsieh J, Ittmann M, Kim WY, Krishnan B, Merino MJ, Shaw KR, Reuter VE, Reznik E, Shelley CS, Shuch B, Signoretti S, Srinivasan R, Tamboli P, Thomas G, Tickoo S, Burnett K, Crain D, Gardner J, Lau K, Mallery D, Morris S, Paulauskis JD, Penny RJ, Shelton C, Shelton WT, Sherman M, Thompson E, Yena P, Avedon MT, Bowen J, Gastier-Foster JM, Gerken M, Leraas KM, Lichtenberg TM, Ramirez NC, Santos T, Wise L, Zmuda E, Demchok JA, Felau I, Hutter CM, Sheth M, Sofia HJ, Tarnuzzer R, Wang Z, Yang L, Zenklusen JC, Zhang J, Ayala B, Baboud J, Chudamani S, Liu J, Lolla L, Naresh R, Pihl T, Sun Q, Wan Y, Wu Y, Ally A, Balasundaram M, Balu S, Beroukhim R, Bodenheimer T, Buhay C, Butterfield YS, Carlsen R, Carter SL, Chao H, Chuah E, Clarke A, Covington KR, Dahdouli M, Dewal N, Dhalla N, Doddapaneni HV, Drummond JA, Gabriel SB, Gibbs RA, Guin R, Hale W, Hawes A, Hayes DN, Holt RA, Hoyle AP, Jefferys SR, Jones SJ, Jones CD, Kalra D, Kovar C, Lewis L, Li J, Ma Y, Marra MA, Mayo M, Meng S, Meyerson M, Mieczkowski PA, Moore RA, Morton D, Mose LE, Mungall AJ, Muzny D, Parker JS, Perou CM, Roach J, Schein JE, Schumacher SE, Shi Y, Simons JV, Sipahimalani P, Skelly T, Soloway MG, Sougnez C, Tam A, Tan D, Thiessen N, Veluvolu U, Wang M, Wilkerson MD, Wong T, Wu J, Xi L, Zhou J, Bedford J, Chen F, Fu Y, Gerstein M, Haussler D, Kasaian K, Lai P, Ling S, Radenbaugh A, Van Den Berg D, Weinstein JN, Zhu J, Albert M, Alexopoulou I, Andersen JJ, Auman JT, Bartlett J, Bastacky S, Bergsten J, Blute ML. Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med, 2015. PMID: 26536169.
18. Hew KE, Miller PC, El-Ashry D, Sun J, Besser AH, Ince TA, Gu M, Wei Z, Zhang G, Brafford P, Gao W, Lu Y, Mills GB, Slingerland JM, Simpkins F. MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in ER-Positive High-Grade Serous Ovarian Cancer. Clin Cancer Res, 2015. PMID: 26482043.
19. Yan X, Hu Z, Feng Y, Hu X, Yuan J, Zhao SD, Zhang Y, Yang L, Shan W, He Q, Fan L, Kandalaft LE, Tanyi JL, Li C, Yuan CX, Zhang D, Yuan H, Hua K, Lu Y, Katsaros D, Huang Q, Montone K, Fan Y, Coukos G, Boyd J, Sood AK, Rebbeck T, Mills GB, Dang CV, Zhang L. Comprehensive Genomic Characterization of Long Non-coding RNAs across Human Cancers. Cancer Cell 28(4):529-40, 2015. PMID: 26461095.
20. Ciriello G, Gatza ML, Beck AH, Wilkerson MD, Rhie SK, Pastore A, Zhang H, McLellan M, Yau C, Kandoth C, Bowlby R, Shen H, Hayat S, Fieldhouse R, Lester SC, Tse GM, Factor RE, Collins LC, Allison KH, Chen YY, Jensen K, Johnson NB, Oesterreich S, Mills GB, Cherniack AD, Robertson G, Benz C, Sander C, Laird PW, Hoadley KA, King TA, TCGA Research Network [Lu Y], Perou CM. Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer. Cell 163(2):506-19, 2015. PMID: 26451490.
21. Han L, Diao L, Yu S, Xu X, Li J, Zhang R, Yang Y, Werner HM, Eterovic AK, Yuan Y, Li J, Nair N, Minelli R, Tsang YH, Cheung LW, Jeong KJ, Roszik J, Ju Z, Woodman SE, Lu Y, Scott KL, Li JB, Mills GB, Liang H. The Genomic Landscape and Clinical Relevance of A-to-I RNA Editing in Human Cancers. Cancer Cell 28(4):515-28, 2015. PMID: 26439496.
22. Liang J, Xu ZX, Ding Z, Lu Y, Yu Q, Werle KD, Zhou G, Park YY, Peng G, Gambello MJ, Mills GB. Myristoylation confers noncanonical AMPK functions in autophagy selectivity and mitochondrial surveillance. Nat Commun 6:7926, 2015. PMID: 26272043.
23. Yang JY, Werner HM, Li J, Westin SN, Lu Y, Halle MK, Trovik J, Salvesen HB, Mills GB, Liang H. Integrative Protein-Based Prognostic Model for Early Stage Endometrioid Endometrial Cancer. Clin Cancer Res, 2015. PMID: 26224872.
24. Timsah Z, Ahmed Z, Ivan C, Berrout J, Gagea M, Zhou Y, Pena GN, Hu X, Vallien C, Kingsley CV, Lu Y, Hancock JF, Liu J, Gladden AB, Mills GB, Lopez-Berestein G, Hung MC, Sood AK, Bogdanov M, Ladbury JE. Grb2 depletion under non-stimulated conditions inhibits PTEN, promotes Akt-induced tumor formation and contributes to poor prognosis in ovarian cancer. Oncogene, 2015. PMID: 26212011.
25. Korkola JE, Collisson EA, Heiser L, Oates C, Bayani N, Itani S, Esch A, Thompson W, Griffith OL, Wang NJ, Kuo WL, Cooper B, Billig J, Ziyad S, Hung JL, Jakkula L, Feiler H, Lu Y, Mills GB, Spellman PT, Tomlin C, Mukherjee S, Gray JW. Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast Cancer. PLoS One 10(7):e0133219, 2015. PMID: 26181325.
26. Cancer Genome Atlas Network [Lu Y]. Genomic Classification of Cutaneous Melanoma. Cell 161(7):1681-96, 2015. PMID: 26091043.
27. Daemen A, Griffith OL, Heiser LM, Wang NJ, Enache OM, Sanborn Z, Pepin F, Durinck S, Korkola JE, Griffith M, Hur JS, Huh N, Chung J, Cope L, Fackler MJ, Umbricht C, Sukumar S, Seth P, Sukhatme VP, Jakkula LR, Lu Y, Mills GB, Cho RJ, Collisson EA, Van't Veer LJ, Spellman PT, Gray JW. Erratum to: Modeling precision treatment of breast cancer. Genome Biol 16:95, 2015. PMID: 25962591.
28. Seviour EG, Sehgal V, Lu Y, Luo Z, Moss T, Zhang F, Hill SM, Liu W, Maiti SN, Cooper L, Azencot R, Lopez-Berestein G, Rodriguez-Aguayo C, Roopaimoole R, Pecot C, Sood AK, Mukherjee S, Gray JW, Mills GB, Ram PT. Functional proteomics identifies miRNAs to target a p27/Myc/phospho-Rb signature in breast and ovarian cancer. Oncogene. e-Pub 2015. PMID: 25639871.
29. Aure MR, Jernström S, Krohn M, Vollan HK, Due EU, Rødland E, Kåresen R, Oslo Breast Cancer Research Consortium (OSBREAC), Ram P, Lu Y, Mills GB, Sahlberg KK, Børresen-Dale AL, Lingjærde OC, Kristensen VN. Integrated analysis reveals microRNA networks coordinately expressed with key proteins in breast cancer. Genome Med 7(1):21, 2015. PMID: 25873999.
30. Boggs AE, Vitolo MI, Whipple RA, Charpentier MS, Goloubeva OG, Ioffe OB, Tuttle KC, Slovic J, Lu Y, Mills GB, Martin SS. α-Tubulin acetylation elevated in metastatic and basal-like breast cancer cells promotes microtentacle formation, adhesion, and invasive migration. Cancer Res 75(1):203-15, 2015. e-Pub 2014. PMID: 25503560.
31. Akbani R, Ng PK, Werner HM, Shahmoradgoli M, Zhang F, Ju Z, Liu W, Yang JY, Yoshihara K, Li J, Ling S, Seviour EG, Ram PT, Minna JD, Diao L, Tong P, Heymach JV, Hill SM, Dondelinger F, Städler N, Byers LA, Meric-Bernstam F, Weinstein JN, Broom BM, Verhaak RG, Liang H, Mukherjee S, Lu Y, Mills GB. Corrigendum: A pan-cancer proteomic perspective on The Cancer Genome Atlas. Nat Commun 6:4852, 2015. PMID: 25629879.
32. Chaluvally-Raghavan P, Zhang F, Pradeep S, Hamilton MP, Zhao X, Rupaimoole R, Moss T, Lu Y, Yu S, Pecot CV, Aure MR, Peuget S, Rodriguez-Aguayo C, Han HD, Zhang D, Venkatanarayan A, Krohn M, Kristensen VN, Gagea M, Ram P, Liu W, Lopez-Berestein G, Lorenzi PL, Børresen-Dale AL, Chin K, Gray J, Dusetti NJ, McGuire SE, Flores ER, Sood AK, Mills GB. Copy number gain of hsa-miR-569 at 3q26.2 leads to loss of TP53INP1 and aggressiveness of epithelial cancers. Cancer Cell 26(6):863-79, 2014. PMID: 25490449.
33. Chiu HS, Llobet-Navas D, Yang X, Chung WJ, Ambesi-Impiombato A, Iyer A, Kim HR, Seviour EG, Luo Z, Sehgal V, Moss T, Lu Y, Ram PT, Silva JM, Mills GB, Califano A, Sumazin P. Cupid: simultaneous reconstruction of microRNA-target and ceRNA networks. Genome Res. e-Pub 2014. PMID: 25378249.
34. Ju Z, Liu W, Roebuck PL, Siwak DR, Zhang N, Lu Y, Davies MA, Akbani R, Weinstein JN, Mills GB, Coombes KR. Development of a robust classifier for quality control of reverse-phase protein arrays. Bioinformatics. e-Pub 2014. PMID: 25380958.
35. Liu S, Meng X, Chen H, Liu W, Miller T, Murph M, Lu Y, Zhang F, Gagea M, Arteaga CL, Mills GB, Meric-Bernstam F, González-Angulo AM. Targeting tyrosine-kinases and estrogen receptor abrogates resistance to endocrine therapy in breast cancer. Oncotarget 5(19):9049-64, 2014. e-Pub 2014. PMID: 24979294.
36. Cheung LW, Yu S, Zhang D, Li J, Ng PK, Panupinthu N, Mitra S, Ju Z, Yu Q, Liang H, Hawke DH, Lu Y, Broaddus RR, Mills GB. Naturally Occurring Neomorphic PIK3R1 Mutations Activate the MAPK Pathway, Dictating Therapeutic Response to MAPK Pathway Inhibitors. Cancer Cell 26(4):479-94, 2014. e-Pub 2014. PMID: 25284480.
37. Cancer Genome Atlas Research Network [Lu Y]. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513(7517):202-9, 2014. PMID: 25079317.
38. Hu X, Feng Y, Zhang D, Zhao SD, Hu Z, Greshock J, Zhang Y, Yang L, Zhong X, Wang LP, Jean S, Li C, Huang Q, Katsaros D, Montone KT, Tanyi JL, Lu Y, Boyd J, Nathanson KL, Li H, Mills GB, Zhang L. A functional genomic approach identifies FAL1 as an oncogenic long noncoding RNA that associates with BMI1 and represses p21 expression in cancer. Cancer Cell 26(3):344-57, 2014. PMID: 25203321.
39. Hoadley KA, Yau C, Wolf DM, Cherniack AD, Tamborero D, Ng S, Leiserson MD, Niu B, McLellan MD, Uzunangelov V, Zhang J, Kandoth C, Akbani R, Shen H, Omberg L, Chu A, Margolin AA, Van't Veer LJ, Lopez-Bigas N, Laird PW, Raphael BJ, Ding L, Robertson AG, Byers LA, Mills GB, Weinstein JN, Van Waes C, Chen Z, Collisson EA, Cancer Genome Atlas Research Network [Lu Y], Benz CC, Perou CM, Stuart JM. Multiplatform Analysis of 12 Cancer Types Reveals Molecular Classification within and across Tissues of Origin. Cell 158(4):929-44, 2014. e-Pub 2014. PMID: 25109877.
40. Cancer Genome Atlas Research Network [Lu Y]. Comprehensive molecular profiling of lung adenocarcinoma. Nature 511(7511):543-50, 2014. PMID: 25079552.
41. Sewell A, Brown B, Biktasova A, Mills GB, Lu Y, Tyson DR, Issaeva N, Yarbrough WG. Reverse Phase Protein Array profiling of oropharyngeal cancer and significance of PIK3CA mutations in HPV-associated head and neck cancer. Clin Cancer Res 20(9):2300-11, 2014. e-Pub 2014. PMID: 24599934.
42. Lui VW, Peyser ND, Ng PK, Hritz J, Zeng Y, Lu Y, Li H, Wang L, Gilbert BR, General IJ, Bahar I, Ju Z, Wang Z, Pendleton KP, Xiao X, Du Y, Vries JK, Hammerman PS, Garraway LA, Mills GB, Johnson DE, Grandis JR. Frequent mutation of receptor protein tyrosine phosphatases provides a mechanism for STAT3 hyperactivation in head and neck cancer. Proc Natl Acad Sci U S A 111(3):1114-9, 2014. e-Pub 2014. PMID: 24395800.
43. Wiegand KC, Hennessy BT, Leung S, Wang Y, Ju Z, McGahren M, Kalloger SE, Finlayson S, Stemke-Hale K, Lu Y, Zhang F, Anglesio MS, Gilks B, Mills GB, Huntsman DG, Carey MS. A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation. BMC Cancer 14(1):120, 2014. e-Pub 2014. PMID: 24559118.
44. Labidi-Galy SI, Clauss A, Ng V, Duraisamy S, Elias KM, Piao HY, Bilal E, Davidowitz RA, Lu Y, Badalian-Very G, Györffy B, Kang UB, Ficarro S, Ganesan S, Mills GB, Marto JA, Drapkin R. Elafin drives poor outcome in high-grade serous ovarian cancers and basal-like breast tumors. Oncogene. e-Pub 2014. PMID: 24469047.
45. Liu W, Ju Z, Lu Y, Mills GB, Akbani R. A comprehensive comparison of normalization methods for loading control and variance stabilization of reverse-phase protein array data. Cancer Inform 13:109-17, 2014. e-Pub 2014. PMID: 25374453.
46. Yu H, Cai S, Gao J, Zhang S, Lu Y, Qiao X, Yang H, Wang Y. Identification and polymorphism discovery of the cathelicidins, Lf-CATHs in ranid amphibian (Limnonectes fragilis). FEBS J 280(23):6022-32, 2013. e-Pub 2013. PMID: 24028327.
47. Li J, Lu Y, Akbani R, Ju Z, Roebuck PL, Liu W, Yang JY, Broom BM, Verhaak RG, Kane DW, Wakefield C, Weinstein JN, Mills GB, Liang H. TCPA: a resource for cancer functional proteomics data. Nat Methods 10(11):1046-7, 2013. e-Pub 2013. PMID: 24037243.
48. Cancer Genome Atlas Research Network [Lu Y], Weinstein JN, Collisson EA, Mills GB, Shaw KR, Ozenberger BA, Ellrott K, Shmulevich I, Sander C, Stuart JM. The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet 45(10):1113-20, 2013. PMID: 24071849.
49. Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, Zheng S, Chakravarty D, Sanborn JZ, Berman SH, Beroukhim R, Bernard B, Wu CJ, Genovese G, Shmulevich I, Barnholtz-Sloan J, Zou L, Vegesna R, Shukla SA, Ciriello G, Yung WK, Zhang W, Sougnez C, Mikkelsen T, Aldape K, Bigner DD, Van Meir EG, Prados M, Sloan A, Black KL, Eschbacher J, Finocchiaro G, Friedman W, Andrews DW, Guha A, Iacocca M, O'Neill BP, Foltz G, Myers J, Weisenberger DJ, Penny R, Kucherlapati R, Perou CM, Hayes DN, Gibbs R, Marra M, Mills GB, Lander E, Spellman P, Wilson R, Sander C, Weinstein J, Meyerson M, Gabriel S, Laird PW, Haussler D, Getz G, Chin L, TCGA Research Network [Lu Y]. The somatic genomic landscape of glioblastoma. Cell 155(2):462-77, 2013. PMID: 24120142.
50. Yang JY, Yoshihara K, Tanaka K, Hatae M, Masuzaki H, Itamochi H, Cancer Genome Atlas (TCGA) Research Network, Takano M, Ushijima K, Tanyi JL, Coukos G, Lu Y, Mills GB, Verhaak RG. Predicting time to ovarian carcinoma recurrence using protein markers. J Clin Invest 123(9):3740-50, 2013. e-Pub 2013. PMID: 23945238.
51. Guo H, Gao M, Lu Y, Liang J, Lorenzi PL, Bai S, Hawke DH, Li J, Dogruluk T, Scott KL, Jonasch E, Mills GB, Ding Z. Coordinate phosphorylation of multiple residues on single AKT1 and AKT2 molecules. Oncogene. e-Pub 2013. PMID: 23912456.
52. Cancer Genome Atlas Research Network [Lu Y]. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499(7456):43-9, 2013. PMID: 23792563.
53. Panupinthu N, Yu S, Zhang D, Zhang F, Gagea M, Lu Y, Grandis JR, Dunn SE, Lee HY, Mills GB. Self-reinforcing loop of amphiregulin and Y-box binding protein-1 contributes to poor outcomes in ovarian cancer. Oncogene. e-Pub 2013. PMID: 23851501.
54. Lui VW, Hedberg ML, Li H, Vangara BS, Pendleton K, Zeng Y, Lu Y, Zhang Q, Du Y, Gilbert BR, Freilino M, Sauerwein S, Peyser ND, Xiao D, Diergaarde B, Wang L, Chiosea S, Seethala R, Johnson JT, Kim S, Duvvuri U, Ferris RL, Romkes M, Nukui T, Kwok-Shing Ng P, Garraway LA, Hammerman PS, Mills GB, Grandis JR. Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. Cancer Discov 3(7):761-9, 2013. PMID: 23619167.
55. Cancer Genome Atlas Research Network [Lu Y], Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, Robertson AG, Pashtan I, Shen R, Benz CC, Yau C, Laird PW, Ding L, Zhang W, Mills GB, Kucherlapati R, Mardis ER, Levine DA. Integrated genomic characterization of endometrial carcinoma. Nature 497(7447):67-73, 2013. PMID: 23636398.
56. Gao M, Liang J, Lu Y, Guo H, German P, Bai S, Jonasch E, Yang X, Mills GB, Ding Z. Site-specific activation of AKT protects cells from death induced by glucose deprivation. Oncogene. e-Pub 2013. PMID: 23396361.
57. Park YY, Kim SB, Han HD, Sohn BH, Kim JH, Liang J, Lu Y, Rodriguez-Aguayo C, Lopez-Berestein G, Mills GB, Sood AK, Lee JS. TARDBP regulates glycolysis in hepatocellular carcinomaby regulating PFKP through miR-520. Hepatology, 2013. PMID: 23389994.
58. Yao Y, Suraokar M, Darnay BG, Hollier BG, Shaiken TE, Asano T, Chen CH, Chang BH, Lu Y, Mills GB, Sarbassov D, Mani SA, Abbruzzese JL, Reddy SA. BSTA promotes mTORC2-mediated phosphorylation of Akt1 to suppress expression of FoxC2 and stimulate adipocyte differentiation. Sci Signal 6(257):ra2, 2013. PMID: 23300339.
59. Jia L, Jin H, Zhou J, Chen L, Lu Y, Ming Y, Yu Y. A potential anti-tumor herbal medicine, Corilagin, inhibits ovarian cancer cell growth through blocking the TGF-β signaling pathways. BMC Complement Altern Med 13:33, 2013. PMID: 23410205.
60. Daemen A, Griffith OL, Heiser LM, Wang NJ, Enache OM, Sanborn Z, Pepin F, Durinck S, Korkola JE, Griffith M, Hur JS, Huh N, Chung J, Cope L, Fackler MJ, Umbricht C, Sukumar S, Seth P, Sukhatme VP, Jakkula LR, Lu Y, Mills GB, Cho RJ, Collisson EA, van't Veer LJ, Spellman PT, Gray JW. Modeling precision treatment of breast cancer. Genome Biol 14(10):R110, 2013. e-Pub 2013. PMID: 24176112.
61. Liu Y, Tao X, Jia L, Cheng KW, Lu Y, Yu Y, Feng Y. Knockdown of RAB25 promotes autophagy and inhibits cell growth in ovarian cancer cells. Mol Med Report 6(5):1006-12, 2012. PMID: 22940905.
62. Liang H, Cheung LW, Li J, Ju Z, Yu S, Stemke-Hale K, Dogruluk T, Lu Y, Liu X, Gu C, Guo W, Scherer SE, Carter H, Westin SN, Dyer MD, Verhaak RG, Zhang F, Karchin R, Liu CG, Lu KH, Broaddus RR, Scott KL, Hennessy BT, Mills GB. Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer. Genome Res 22(11):2120-9, 2012. PMID: 23028188.
63. Simpkins F, Hevia-Paez P, Sun J, Ullmer W, Gilbert CA, da Silva T, Pedram A, Levin ER, Reis IM, Rabinovich B, Azzam D, Xu XX, Ince TA, Yang JY, Verhaak RG, Lu Y, Mills GB, Slingerland JM. Src Inhibition with saracatinib reverses fulvestrant resistance in ER-positive ovarian cancer models in vitro and in vivo. Clin Cancer Res 18(21):5911-23, 2012. PMID: 22896656.
64. Hill SM, Lu Y, Molina J, Heiser LM, Spellman PT, Speed TP, Gray JW, Mills GB, Mukherjee S. Bayesian inference of signaling network topology in a cancer cell line. Bioinformatics 28(21):2804-10, 2012. PMID: 22923301.
65. Cancer Genome Atlas Network [Lu Y]. Comprehensive molecular portraits of human breast tumours. Nature 490(7418):61-70, 2012. PMID: 23000897.
66. Oates CJ, Hennessy BT, Lu Y, Mills GB, Mukherjee S. Network Inference Using Steady-State Data and Goldbeter-Koshland Kinetics. Bioinformatics 28(18):2342-8, 2012. PMID: 22815361.
67. Nieto-Barajas LE, Müller P, Ji Y, Lu Y, Mills GB. A time-series DDP for functional proteomics profiles. Biometrics 68(3):859-68, 2012. e-Pub 2012. PMID: 22221181.
68. Tarcic G, Avraham R, Pines G, Amit I, Shay T, Lu Y, Zwang Y, Katz M, Ben-Chetrit N, Jacob-Hirsch J, Virgilio L, Rechavi G, Mavrothalassitis G, Mills GB, Domany E, Yarden Y. EGR1 and the ERK-ERF axis drive mammary cell migration in response to EGF. FASEB J 26(4):1582-92, 2012. e-Pub 2011. PMID: 22198386.
69. Kim N, He N, Kim C, Zhang F, Lu Y, Yu Q, Stemke-Hale K, Greshock J, Wooster R, Yoon S, Mills GB. Systematic analysis of genotype-specific drug responses in cancer. Int J Cancer, 2012. PMID: 22422301.
70. Duong MT, Akli S, Wei C, Wingate HF, Liu W, Lu Y, Yi M, Mills GB, Hunt KK, Keyomarsi K. LMW-E/CDK2 deregulates acinar morphogenesis, induces tumorigenesis, and associates with the activated b-Raf-ERK1/2-mTOR pathway in breast cancer patients. PLoS Genet 8(3):e1002538, 2012. PMID: 22479189.
71. He Y, Zhou Z, Hofstetter WL, Zhou Y, Hu W, Guo C, Wang L, Guo W, Pataer A, Correa AM, Lu Y, Wang J, Diao L, Byers LA, Wistuba II, Roth JA, Swisher SG, Heymach JV, Fang B. Aberrant expression of proteins involved in signal transduction and DNA repair pathways in lung cancer and their association with clinical parameters. PLoS One 7(2):e31087, 2012. PMID: 22348039.
72. Claerhout S, Dutta B, Bossuyt W, Zhang F, Nguyen-Charles C, Dennison JB, Yu Q, Yu S, Balázsi G, Lu Y, Mills GB. Abortive autophagy induces endoplasmic reticulum stress and cell death in cancer cells. PLoS One 7(6):e39400, 2012. e-Pub 2012. PMID: 22745748.
73. Park YY, Kim K, Kim SB, Hennessy BT, Kim SM, Park ES, Lim JY, Li J, Lu Y, Gonzalez-Angulo AM, Jeong W, Mills GB, Safe S, Lee JS. Reconstruction of nuclear receptor network reveals that NR2E3 is a novel upstream regulator of ESR1 in breast cancer. EMBO Mol Med 4(1):52-67, 2012. PMID: 22174013.
74. Guo H, Liu W, Ju Z, Tamboli P, Jonasch E, Mills GB, Lu Y, Hennessy BT, Tsavachidou D. An efficient procedure for protein extraction from formalin-fixed, paraffin-embedded tissues for reverse phase protein arrays. Proteome Sci 10(1):56, 2012. PMID: 23006314.
75. Hoshino D, Jourquin J, Emmons SW, Miller T, Goldgof M, Costello K, Tyson DR, Brown B, Lu Y, Prasad NK, Zhang B, Mills GB, Yarbrough WG, Quaranta V, Seiki M, Weaver AM. Network analysis of the focal adhesion to invadopodia transition identifies a PI3K-PKCα invasive signaling axis. Sci Signal 5(241):ra66, 2012. PMID: 22969158.
76. Cheong JH, Park ES, Liang J, Dennison JB, Tsavachidou D, Nguyen-Charles C, Wa Cheng K, Hall H, Zhang D, Lu Y, Ravoori M, Kundra V, Ajani J, Lee JS, Ki Hong W, Mills GB. Dual Inhibition of Tumor Energy Pathway by 2-Deoxyglucose and Metformin Is Effective against a Broad Spectrum of Preclinical Cancer Models. Mol Cancer Ther 10(12):2350-62, 2011. PMID: 21992792.
77. Lu Y, Muller M, Smith D, Dutta B, Komurov K, Iadevaia S, Ruths D, Tseng JT, Yu S, Yu Q, Nakhleh L, Balazsi G, Donnelly J, Schurdak M, Morgan-Lappe S, Fesik S, Ram PT, Mills GB. Kinome siRNA-phosphoproteomic screen identifies networks regulating AKT signaling. Oncogene 30(45):4567-77, 2011. PMID: 21666717.
78. Cheung LW, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B, Lu Y, Stemke-Hale K, Dyer MD, Zhang F, Ju Z, Cantley LC, Scherer SE, Liang H, Lu KH, Broaddus RR, Mills GB. High Frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. Cancer Discov 1(2):170-85, 2011. PMID: 21984976.
79. Zwang Y, Sas-Chen A, Drier Y, Shay T, Avraham R, Lauriola M, Shema E, Lidor-Nili E, Jacob-Hirsch J, Amariglio N, Lu Y, Mills GB, Rechavi G, Oren M, Domany E, Yarden Y. Two Phases of Mitogenic Signaling Unveil Roles for p53 and EGR1 in Elimination of Inconsistent Growth Signals. Mol Cell 42(4):524-35, 2011. PMID: 21596316.
80. Gupte R, Siddam A, Lu Y, Li W, Fujiwara Y, Panupinthu N, Pham TC, Baker DL, Parrill AL, Gotoh M, Murakami-Murofushi K, Kobayashi S, Mills GB, Tigyi G, Miller DD. Synthesis and pharmacological evaluation of the stereoisomers of 3-carba cyclic-phosphatidic acid. Bioorg Med Chem Lett 20(24):7525-8, 2010. PMID: 21051230.
81. Hennessy BT, Lu Y, Gonzalez-Angulo AM, Carey MS, Myhre S, Ju Z, Davies MA, Liu W, Coombes K, Meric-Bernstam F, Bedrosian I, McGahren M, Agarwal R, Zhang F, Overgaard J, Alsner J, Neve RM, Kuo WL, Gray JW, Borresen-Dale AL, Mills GB. A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast Cancers. Clin Proteomics 6(4):129-151, 2010. PMID: 21691416.
82. Iadevaia S, Lu Y, Morales FC, Mills GB, Ram PT. Identification of optimal drug combinations targeting cellular networks: integrating phospho-proteomics and computational network analysis. Cancer Res 70(17):6704-14, 2010. PMID: 20643779.
83. Koul D, Shen R, Kim YW, Kondo Y, Lu Y, Bankson J, Ronen SM, Kirkpatrick DL, Powis G, Yung WK. Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma. Neuro Oncol 12(6):559-69, 2010. PMID: 20156803.
84. Huang S, Chang IS, Lin W, Ye W, Luo RZ, Lu Z, Lu Y, Zhang K, Liao WS, Tao T, Bast RC, Chen X, Yu Y. ARHI (DIRAS3), an imprinted tumour suppressor gene, binds to importins and blocks nuclear import of cargo proteins. Biosci Rep 30(3):159-68, 2010. PMID: 19435463.
85. Carey MS, Agarwal R, Gilks B, Swenerton K, Kalloger S, Santos J, Ju Z, Lu Y, Zhang F, Coombes KR, Miller D, Huntsman D, Mills GB, Hennessy BT. Functional proteomic analysis of advanced serous ovarian cancer using reverse phase protein array: TGF-beta pathway signaling indicates response to primary chemotherapy. Clin Cancer Res 16(10):2852-60, 2010. PMID: 20460476.
86. Mazzone M, Selfors LM, Albeck J, Overholtzer M, Sale S, Carroll DL, Pandya D, Lu Y, Mills GB, Aster JC, Artavanis-Tsakonas S, Brugge JS. Dose-dependent induction of distinct phenotypic responses to Notch pathway activation in mammary epithelial cells. Proc Natl Acad Sci U S A 107(11):5012-7, 2010. PMID: 20194747.
87. Hong B, Lui VW, Hui EP, Lu Y, Leung HS, Wong EY, Cheng SH, Ng MH, Mills GB, Chan AT. Reverse phase protein array identifies novel anti-invasion mechanisms of YC-1. Biochem Pharmacol 79(6):842-52, 2010. PMID: 19879857.
88. Park ES, Rabinovsky R, Carey M, Hennessy BT, Agarwal R, Liu W, Ju Z, Deng W, Lu Y, Woo HG, Kim SB, Cheong JH, Garraway LA, Weinstein JN, Mills GB, Lee JS, Davies MA. Integrative analysis of proteomic signatures, mutations, and drug responsiveness in the NCI 60 cancer cell line set. Mol Cancer Ther 9(2):257-67, 2010. PMID: 20124458.
89. Spizzo R, Nicoloso MS, Lupini L, Lu Y, Fogarty J, Rossi S, Zagatti B, Fabbri M, Veronese A, Liu X, Davuluri R, Croce CM, Mills G, Negrini M, Calin GA. miR-145 participates with TP53 in a death-promoting regulatory loop and targets estrogen receptor-alpha in human breast cancer cells. Cell Death Differ 17(2):246-54, 2010. PMID: 19730444.
90. Irie HY, Shrestha Y, Selfors LM, Frye F, Iida N, Wang Z, Zou L, Yao J, Lu Y, Epstein CB, Natesan S, Richardson AL, Polyak K, Mills GB, Hahn WC, Brugge JS. PTK6 regulates IGF-1-induced anchorage-independent survival. PLoS One 5(7):e11729, 2010. PMID: 20668531.
91. Ding Z, Liang J, Li J, Lu Y, Ariyaratna V, Lu Z, Davies MA, Westwick JK, Mills GB. Physical association of PDK1 with AKT1 is sufficient for pathway activation independent of membrane localization and phosphatidylinositol 3 kinase. PLoS One 5(3):e9910, 2010. PMID: 20361045.
92. Vasudevan KM, Barbie DA, Davies MA, Rabinovsky R, McNear CJ, Kim JJ, Hennessy BT, Tseng H, Pochanard P, Kim SY, Dunn IF, Schinzel AC, Sandy P, Hoersch S, Sheng Q, Gupta PB, Boehm JS, Reiling JH, Silver S, Lu Y, Stemke-Hale K, Dutta B, Joy C, Sahin AA, Gonzalez-Angulo AM, Lluch A, Rameh LE, Jacks T, Root DE, Lander ES, Mills GB, Hahn WC, Sellers WR, Garraway LA. AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell 16(1):21-32, 2009. PMID: 19573809.
93. Shahzad MM, Lu C, Lee JW, Stone RL, Mitra R, Mangala LS, Lu Y, Baggerly KA, Danes CG, Nick AM, Halder J, Kim HS, Vivas-Mejia P, Landen CN, Lopez-Berestein G, Coleman RL, Sood AK. Dual targeting of EphA2 and FAK in ovarian carcinoma. Cancer Biol Ther 8(11):1027-34, 2009. PMID: 19395869.
94. Liu S, Umezu-Goto M, Murph M, Lu Y, Liu W, Zhang F, Yu S, Stephens LC, Cui X, Murrow G, Coombes K, Muller W, Hung MC, Perou CM, Lee AV, Fang X, Mills GB. Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases. Cancer Cell 15(6):539-50, 2009. PMID: 19477432.
95. Wei X, Guo W, Wu S, Wang L, Lu Y, Xu B, Liu J, Fang B. Inhibiting JNK dephosphorylation and induction of apoptosis by novel anticancer agent NSC-741909 in cancer cells. J Biol Chem 284(25):16948-55, 2009. PMID: 19414586.
96. Yim EK, Peng G, Dai H, Hu R, Li K, Lu Y, Mills GB, Meric-Bernstam F, Hennessy BT, Craven RJ, Lin SY. Rak functions as a tumor suppressor by regulating PTEN protein stability and function. Cancer Cell 15(4):304-14, 2009. PMID: 19345329.
97. Murph MM, Liu W, Yu S, Lu Y, Hall H, Hennessy BT, Lahad J, Schaner M, Helland A, Kristensen G, Børresen-Dale AL, Mills GB. Lysophosphatidic acid-induced transcriptional profile represents serous epithelial ovarian carcinoma and worsened prognosis. PLoS One 4(5):e5583, 2009. PMID: 19440550.
98. Lu Z, Luo RZ, Lu Y, Zhang X, Yu Q, Khare S, Kondo S, Kondo Y, Yu Y, Mills GB, Liao WS, Bast RC. The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cells. J Clin Invest 118(12):3917-29, 2008. PMID: 19033662.
99. Yu S, Murph MM, Lu Y, Liu S, Hall HS, Liu J, Stephens C, Fang X, Mills GB. Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells. J Natl Cancer Inst 100(22):1630-42, 2008. PMID: 19001604.
100. Zhu QS, Ren W, Korchin B, Lahat G, Dicker A, Lu Y, Mills G, Pollock RE, Lev D. Soft tissue sarcoma cells are highly sensitive to AKT blockade: a role for p53-independent up-regulation of GADD45 alpha. Cancer Res 68(8):2895-903, 2008. PMID: 18413758.
101. Ji Y, Lu Y, Mills GB. Bayesian methods based on test statistics for multiple hypothesis testing problems. Bioinformatics 24(7):943-949, 2008. PMID: 18245123.
102. Garlich, JR, De P, Dey N, Su JD, Peng X, Miller A, Murali R, Lu Y, Mills GB. A vascular targeted pan phosphoinositides 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity. Cancer Research 68(1):206-215, 2008. PMID: 18172313.
103. Gajewiak J, Tsukahara R, Tsukahara T, Fujiwara Y, Yu S, Lu Y, Murph M, Mills GB, Tigyi G, Prestwich GD. Alkoxymethylenephosphonate analogues of (lyso) phosphatidic acid stimulate signaling networks coupled to the LPA(2) receptor. ChemMedChem 3(2):200, 2007. PMID: 17952880.
104. Hennessy BT, Lu Y, Poradosu E, Yu Q, Yu S, Hall H, Carey MS, Ravoori M, Gonzalez-Angulo AM, Birch R, Henderson IC, Kundra V, Mills GB. Pharmacodynamic markers of perifosine efficacy. Clin Cancer Res 13(24):7421-31, 2007. PMID: 18094426.
105. Amit I, Citri A, Shay T, Lu Y, Katz M, Zhang F, Tarcic G, Siwak D, Lahad J, Jacob-Hirsch J, Amariglio N, Vaisman N, Segal E, Rechavi G, Alon U, Mills GB, Domany E, Yarden Y. A module of negative feedback regulators defines growth factor signaling. Nat Genet 39(4):503-12, 2007. PMID: 17322878.
106. Ding Z, Liang J, Lu Y, Yu Q, Songyang Z, Lin SY, Mills GB. ACTN4 Regulates AKT1 Function: A Retrovirus-Based Protein Mammalian Complementation Assay Screen Reveals Novel AKT1 Binding Partners. Proc Natl Acad Sci U S A 103(41):15014-19, 2006. PMID: 17018644.
107. Tibes R, Qiu Y, Lu Y, Hennessy B, Andreeff M, Mills GB, Kornblau SM. Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol Cancer Ther 5(10):2512-21, 2006. PMID: 17041095.
108. Zeng Z, Samudio IJ, Zhang W, Estrov Z, Pelicano H, Harris D, Frolova O, Hail N, Chen W, Kornblau SM, Huang P, Lu Y, Mills GB, Andreeff M, Konopleva M. Simultaneous inhibition of PDK1/AKT and Fms-like tyrosine kinase 3 signaling by a small-molecule KP372-1 induces mitochondrial dysfunction and apoptosis in acute myelogenous leukemia. Cancer Res 66(7):3737-3746, 2006. PMID: 16585200.
109. Koul D, Shen R, Bergh S, Sheng X, Shishodia S, Lafortune TA, Lu Y, de Groot JF, Mills GB, Yung WK. Inhibition of Akt survival pathway by a small-molecule inhibitor in human glioblastoma. Mol Cancer Ther 5(3):637-644, 2006. PMID: 16546978.
110. Visentin B, Vekich JA, Sibbald BJ, Cavalli AL, Moreno KM, Matteo RG, Garland WA, Lu Y, Yu S, Hall HS, Kundra V, Mills GB, Sabbadini RA. Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. Cancer Cell 9(3):225-238, 2006. PMID: 16530706.
111. Koul D, Shen R, Bergh S, Lu Y, de Groot JF, Liu TJ, Mills GB, Yung WK. Targeting integrin-linked kinase inhibits Akt signaling pathways and decreases tumor progression of human glioblastoma. Mol Cancer Ther 4(11):1681-1686, 2005. PMID: 16275989.
112. Sheehan KM, Calvert VS, Kay EW, Lu Y, Fishman D, Espina V, Aquino J, Speer R, Araujo R, Mills GB, Liotta LA, Petricoin EF, Wulfkuhle JD. Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma. Mol Cell Proteomics 4(4):346-55, 2005. PMID: 15671044.
113. Le XF, Lammayot A, Gold D, Lu Y, Mao W, Chang T, Patel A, Mills GB, Bast RC. Genes affecting the cell cycle, growth, maintenance, and drug sensitivity are preferentially regulated by anti-HER2 antibody through phosphatidylinositol 3-kinase-AKT signaling. J Biol Chem 280(3):2092-104, 2005. PMID: 15504738.
114. Fang X, Yu S, Bast RC, Liu S, Xu HJ, Hu SX, LaPushin R, Claret FX, Aggarwal BB, Lu Y, Mills GB. Mechanisms for lysophosphatidic acid-induced cytokine production in ovarian cancer cells. J Biol Chem 279(10):9653-61, 2004. PMID: 14670967.
115. Lu Y, Yu Q, Liu JH, Zhang J, Wang H, Koul D, McMurray JS, Fang X, Yung WK, Siminovitch KA, Mills GB. Src family protein-tyrosine kinases alter the function of PTEN to regulate phosphatidylinositol 3-kinase/AKT cascades. J Biol Chem 278(41):40057-66, 2003. PMID: 12869565.
116. Lee HY, Srinivas H, Xia D, Lu Y, Superty R, LaPushin R, Gomez-Manzano C, Gal AM, Walsh GL, Force T, Ueki K, Mills GB, Kurie JM. Evidence that phosphatidylinositol 3-kinase- and mitogen-activated protein kinase kinase-4/c-Jun NH2-terminal kinase-dependent Pathways cooperate to maintain lung cancer cell survival. J Biol Chem 278(26):23630-8, 2003. PMID: 12714585.
117. Cui X, Zhang P, Deng W, Oesterreich S, Lu Y, Mills GB, Lee AV. Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer. Mol Endocrinol 17(4):575-88, 2003. PMID: 12554765.
118. Fang X, Yu S, Tanyi JL, Lu Y, Woodgett JR, Mills GB. Convergence of multiple signaling cascades at glycogen synthase kinase 3: Edg receptor-mediated phosphorylation and inactivation by lysophosphatidic acid through a protein kinase C-dependent intracellular pathway. Mol Cell Biol 22(7):2099-110, 2002. PMID: 11884598.
119. Koul D, Jasser SA, Lu Y, Davies MA, Shen R, Shi Y, Mills GB, Yung WK. Motif analysis of the tumor suppressor gene MMAC/PTEN identifies tyrosines critical for tumor suppression and lipid phosphatase activity. Oncogene 21(15):2357-64, 2002. PMID: 11948419.
120. Hu L, Hofmann J, Lu Y, Mills GB, Jaffe RB. Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res 62(4):1087-92, 2002. PMID: 11861387.
121. Liu B, Fang M, Lu Y, Lu Y, Mills GB, Fan Z. Involvement of JNK-mediated pathway in EGF-mediated protection against paclitaxel-induced apoptosis in SiHa human cervical cancer cells. Br J Cancer 85(2):303-11, 2001. PMID: 11461094.
122. Cuevas BD, Lu Y, Mao M, Zhang J, LaPushin R, Siminovitch K, Mills GB. Tyrosine phosphorylation of p85 relieves its inhibitory activity on phosphatidylinositol 3-kinase. J Biol Chem 276:27455-61, 2001. PMID: 11337495.
123. Mujoo K, Haridas V, Hoffmann JJ, Wachter GA, Hutter LK, Lu Y, Blake ME, Jayatilake GS, Bailey D, Mills GB, Gutterman JU. Triterpenoid saponins from Acacia victoriae (Bentham) decrease tumor cell proliferation and induce apoptosis. Cancer Res 61:5486-90, 2001. PMID: 11454696.
124. Fang X, Yu S, LaPushin R, Lu Y, Furui T, Penn LZ, Stokoe D, Erickson JR, Bast RC, Mills GB. Lysophosphatidic acid prevents apoptosis in fibroblasts via G(i)-protein-mediated activation of mitogen-activated protein kinase. Biochem J 352(Pt 1):135-43, 2000. PMID: 11062066.
125. Fang X, Yu SX, Lu Y, Bast RC, Woodgett JR, Mills GB. Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A. Proc Natl Acad Sci U S A 97(22):11960-5, 2000. PMID: 11035810.
126. Mao M, Fang X, Lu Y, Lapushin R, Bast RC Jr, Mills GB. Inhibition of growth-factor-induced phosphorylation and activation of protein kinase B/Akt by atypical protein kinase C in breast cancer cells. Biochem J 352(Pt 2):475-82, 2000. PMID: 11085941.
127. Cuevas B, Lu Y, Watt S, Kumar R, Zhang J, Siminovitch KA, Mills GB. SHP-1 regulates Lck-induced phosphatidylinositol 3-kinase phosphorylation and activity. J Biol Chem 274:27583-9, 1999. PMID: 10488096.
128. Furui T, LaPushin R, Mao M, Khan H, Watt SR, Watt MA, Lu Y, Fang X, Tsutsui S, Siddik ZH, Bast RC, Mills GB. Overexpression of edg-2/vzg-1 induces apoptosis and anoikis in ovarian cancer cells in a lysophosphatidic acid-independent manner. Clin Cancer Res 5:4308-18, 1999. PMID: 10632375.
129. Lu Y, Lin YZ, LaPushin R, Cuevas B, Fang X, Yu SX, Davies MA, Khan H, Furui T, Mao M, Zinner R, Hung MC, Steck P, Siminovitch K, Mills GB. The PTEN/MMAC1/TEP tumor suppressor gene decreases cell growth and induces apoptosis and anoikis in breast cancer cells. Oncogene 18:7034-45, 1999. PMID: 10597304.
130. Lu Y, Shayesteh L, Kuo WL, Baldocchi R, Godfrey T, Collins C, Pinkel D, Powell B, Mills GB, Gray JW. PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 21:99-102, 1999. PMID: 9916799.
131. Lu Y, Davies MA, Sano T, Fang X, Tang P, LaPushin R, Koul D, Bookstein R, Stokoe D, Yung WK, Mills GB, Steck PA. Adenoviral transgene expression of MMAC/PTEN in human glioma cells inhibits Akt activation and induces anoikis. Cancer Res 58:5285-90, 1998. PMID: 9850049.
132. Gibson S, Truitt K, Lu Y, Lapushin R, Khan H, Imboden JB, Mills GB. Efficient CD28 signalling leads to increases in the kinase activities of the TEC family tyrosine kinase EMT/ITK/TSK and the SRC family tyrosine kinase LCK. Biochem J 330(Pt 3):1123-8, 1998. PMID: 9494076.
133. Lu Y, Cuevas B, Gibson S, Khan H, LaPushin R, Imboden J, Mills GB. Phosphatidylinositol 3-kinase is required for CD28 but not CD3 regulation of the TEC family tyrosine kinase EMT/ITK/TSK: functional and physical interaction of EMT with phosphatidylinositol 3-kinase. J Immunol 161:5404-12, 1998. PMID: 9820515.
134. Lu Y, Rodriguez R, Bjorndahl J, Phillips CA, Trevillyan JM. CD28-dependent killing by human YT cells requires phosphatidylinositol 3-kinase activation. Eur J Immunol 26:1278-84, 1996. PMID: 8647205.
135. Lu Y, Phillips CA, Trevillyan JM. Phosphatidylinositol 3-kinase activity is not essential for CD28 costimulatory activity in Jurkat T cells: studies with a selective inhibitor, wortmannin. Eur J Immunol 25:533-7, 1995. PMID: 7875216.
136. Lu Y, Phillips CA, Bjorndahl JM, Trevillyan JM. CD28 signal transduction: tyrosine phosphorylation and receptor association of phosphoinositide-3 kinase correlate with Ca(2+)-independent costimulatory activity. Eur J Immunol 24:2732-9, 1994. PMID: 7957566.
137. Cone JC, Lu Y, Trevillyan JM, Bjorndahl JM, Phillips CA. Association of the p56lck protein tyrosine kinase with the Fc gamma RIIIA/CD16 complex in human natural killer cells. Eur J Immunol 23:2488-97, 1993. PMID: 8405050.
138. Dombrowski KE, Trevillyan JM, Cone JC, Lu Y, Phillips CA. Identification and partial characterization of an ectoATPase expressed by human natural killer cells. Biochemistry 32:6515-22, 1993. PMID: 8329381.
139. Lu Y, Granelli-Piperno A, Bjorndahl JM, Phillips CA, Trevillyan JM. CD28-induced T cell activation. Evidence for a protein-tyrosine kinase signal transduction pathway. J Immunol 149:24-9, 1992. PMID: 1318900.
140. Trevillyan J, Lu Y, Phillips CA. T-lymphocyte activation. Panhandle Health 3:10-11, 1992.
141. Trevillyan JM, Lu YL, Atluru D, Phillips CA, Bjorndahl JM. Differential inhibition of T cell receptor signal transduction and early activation events by a selective inhibitor of protein-tyrosine kinase. J Immunol 145:3223-30, 1990. PMID: 2172380.
142. Lu Y, Ma BL, Jin YC. Significance of several immunologic tests in diagnosis of Trichosanthin induced anaphylaxis. J.Shanghai Immunology 8:86-90, 1988.
143. Lu Y, Ma BL, Jin YC. Influence of several factors on human immune response to Trichosanthin. J. Shanghai Immunology 8:166-169, 1988.
144. Lu Y, Ma BL. Clinical application of monoclonal antibodies. J. Shanghai Immunology 1:59-62, 1981.
145. Lu Y, Wang WC, Xie YL. Detection of human SmIgG on B lymphocytes in peripheral blood with FITC conjugated protein. J. Shanghai Immunology 1:24, 1981.
146. Liang J, Xu Z-X, Ding Z, Lu Y, Yu Q, Zhou G, Gambello MJ. AMPK regulates autophagy selectivity and mitochondrial surveillance proliferating cells.
147. Hill SM, Lu Y, Molina J, Spellman PT, Gray JW, Mills GB, Mukherjee S. Data-driven characterization of signaling networks in individual.

Invited Articles

1. Murph MM, Smith DL, Hennessy B, Lu Y, Joy C, Coombes KR, Mills GB. Individualized molecular medicine: Linking functional proteomics to select therapeutics targeting the PI3K pathway for specific patients. Adv Exp Med Biol 622(622):183-95, 2008. PMID: 18546628.
2. Hennessy BT, Murph M, Nanjundan M, Carey M, Auersperg N, Almeida J, Coombes KR, Liu J, Lu Y, Gray JW, Mills GB. Ovarian cancer: Linking Genomics to New Target Discovery and Molecular Markers--The Way Ahead. Adv Exp Med Biol 617(617):23-40, 2008. PMID: 18497028.
3. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 4(12)(12):988-1004, 2005. PMID: 16341064.
4. Cheng KW, Lu Y, Mills GB. Assay of Rab25 function in ovarian and breast cancers. Methods Enzymol 403:202-215, 2005. PMID: 16473588.
5. Umezu-Goto M, Tanyi J, Lahad J, Liu S, Yu S, Lapushin R, Hasegawa Y, Lu Y, Trost R, Bevers T, Jonasch E, Aldape K, Liu J, James RD, Ferguson CG, Xu Y, Prestwich GD, Mills GB. Lysophosphatidic acid production and action: Validated targets in cancer. J Cell Biochem 92(6)(6):1115-1140, 2004. PMID: 15258897.
6. Kohn EC, Lu Y, Wang H, Yu Q, Yu S, Hall H, Smith DL, Meric-Bernstam F, Hortobagyi GN, Mills GB. Molecular therapeutics: promise and challenges. Semin Oncol 31(1 Suppl 3):39-53, 2004. PMID: 15052542.
7. Mills GB, Kohn E, Lu Y, Eder A, Fang X, Wang H, Bast RC, Gray J, Jaffe R, Hortobagyi G. Linking molecular diagnostics to molecular therapeutics: Targeting the PI3K pathway in breast cancer. Semin Oncol 30(5 Suppl 16):93-104, 2003. PMID: 14613030.
8. Lu Y, Wang H, Mills GB. Targeting PI3K/AKT pathway for cancer therapy. Rev Clin Exp Hematol 7(2):205-228, 2003. PMID: 14763163.
9. Mills GB, Fang X, Lu Y, Hasegawa Y, Eder A, Tanyi J, Tabassam FH, Mao M, Wang H, Cheng KW, Nakayama Y, Kuo W, Erickson J, Gershenson D, Kohn EC, Jaffe R, Bast RC, Gray J. Specific keynote: molecular therapeutics in ovarian cancer. Gynecol Oncol 88(1 Pt 2):S88-92; discussion S93-6, 2003. PMID: 12586094.
10. Lu Y, Shayestri L, LaPushin R, Yu S, Cuevas B, Fang X, Eder A, Furui T, Plikoff D, Kuo WL, Baldocchi R, Vanhaesebroeck B, Bast RC, Pinkel D, Siminovitch K, Jaffe R, Gray J, Mills GB. Phosphatidylinositol 3'kinase as a Target in Selected Ovarian Cancers: From Genomics to Therapeutics. In Ovarian Cancer Oxford University Press:413-422, 2002.
11. Mills GB, Eder A, Fang X, Hasegawa Y, Mao M, Lu Y, Tanyi J, Tabassam FH, Wiener J, Lapushin R, Yu S, Parrott JA, Compton T, Tribley W, Fishman D, Stack MS, Gaudette D, Jaffe R, Furui T, Aoki J, Erickson JR. Critical role of Lysophospholipids in the Pathophysiology Diagnosis, and Management of Ovarian Cancer. Cancer Treat Res 107:259-83, 2002. PMID: 11775454.
12. Mills GB, Lu Y, Fang X, Wang H, Eder A, Mao M, Swaby R, Cheng KW, Stokoe D, Jaffe R, Gray J, Siminovitch K. The role of genetic abnormalities of PTEN and the phosphatidylinositol 3-kinase pathway in breast and ovarian tumorigenesis, prognosis, and therapy. Semin Oncol 28:125-41, 2001. PMID: 11706404.
13. Mills GB, Lu Y, Kohn EC. Linking molecular therapeutics to molecular diagnostics: inhibition of the FRAP/RAFT/TOR component of the PI3K pathway preferentially blocks PTEN mutant cells in vitro and in vivo. Proc Natl Acad Sci U S A 98:10031-3, 2001. PMID: 11526226.
14. Mills GB, Lu Y, Shyestri L, Pinkel D, Gray J. From genetics to therapeutic targets: Phosphatidylinositol 3 kinase (PI3K) in ovarian and breast cancer. Cancer: investigatcion basica y aplicaciones clinicas:6-16, 1999.
15. Xu Y, Fang X, Furui T, Sasagawa T, Pustilnik T, Lu Y, Shen Z, Wiener JR, Shayesteh L, Gray JW, Bast Jr RC, Mills GB. Regulation of growth of ovarian cancer cells by phospholipid growth factors. Ovarian Cancer 5:109-120, 1998.

Abstracts

1. Lu Y, Morgan-Lappe S, Yu Q, Yu S, Luo Y, Liu W, Joy C, Fesik S, Mills GB. Identify on and off target effects of targeted therapeutics on signaling networks by RPPA. Proceedings of AACR Annual Meeting 48, 2007.
2. Lu Y, Hennessy B, Siwak D, Tibes R, Yu Q, Yu S, Mills GB. Reverse phase protein microarrays is sensitive, stable and quantitative in clinical application. Proceedings of the 97th Annual Meeting of the American Association for Cancer Research, 2006.
3. Lu Y, Su JD, Yu Q, Yu S, Rovori M, Kundra V, Miller T, Patterson M, Garlich J, Mills GB. Identification of molecular markers for selection of patients likely to respond and parmacodynamic markers of delivery of biologically relevant dose and early response to a novel phosphatidylinositol 3-kinase (PI3K) inhibitory prodrug, SF1126. Proceedings of the 9th Annual Meeting of the American Association for Cancer Research, 2006.
4. Lu Y, Ruan M, Mills G. Sensitivity and Stability studies for the reverse phase protein microarray technology applied in clinical diagnosis. Proceedings of the CHI Conference on Proteomics, 2005.
5. Lu Y, Yu QH, Hassan H, Yu S, LaPushin R, Mills GB. Tissue lysate arrays as a cell-based assay for molecular screening of AKT inhibitors. Proceedings of the 16th EORTC-NCI AACR Symposium on Molecular Targeted Cancer Therapeutics, 2004.
6. Lu Y, Yu QH, Hall H, Mills GB. Inhibition of PI3K-AKT pathway as a therapeutic target for breast cancer. Proceedings of the 94th Annual Meeting of the American Association for Cancer Research, 2003.
7. Lu Y, Liu JH, Zhang JY, Wang H, Koul D, McMurray JS, Fang XJ, Yung WA, Simnovitch KA, Mills GB. Involvement of the Src family protein tyrosine kinases and the SHP-1 tyrosine phosphatase in the phosphotyrosine-dependent regulation of the PTEN activity. Proceeding of the 93rd Annual Meeting of the American Association for Cancer Research, 2002.
8. Lu Y, Cuevas B, Lin YZ, Koul D, Steck PA, Siminovitch K, Mills GB. Functional Interaction of the SHP1 SH2 Domain containing tyrosine phosphatase with the PTEN tumor suppressor gene is regulated by growth factors. Proceedings of the 91st Annual Meeting of the American Association for Cancer Research, 2000.
9. Lu Y, Lin YZ, LaPushin R, Fang X, Yu S, Davies MA, Khan H, Cuevas B, Furui T, Mao M, Zinner R, Hung MC, Steck PA, Mills GB. The MMAC1/PTEN tumor suppressor gene negatively regulates P13K-dependent signaling in breast cancer cells. Proceedings of the the AACR Annual Meeting, Philadelphia 40:685, 1999.
10. Wu JY, Xu FJ, Yu YH, Lu Y, Bast RC. Differential signaling induced by heregulin and antibodies to p185c-erbB-2 (p185HER-2) in SKBr3 breast cancer cells that overexpress the receptor. Proceedings of the 89th Annual Meeting of the American Association for Cancer Research 39:471, 1998.
11. Shayesteh L, Lu Y, Kuo WL, Collins C, Pinkel D, Mills GB, Gray JW. PIK3CA is implicated as an oncogene in ovarian cancer. Proceedings of the 89th Annual Meeting of the American Association for Cancer Research, New Orleans 39:471, 1998.
12. Lu Y, Wu JY, LaPushin R, Mills GB, Xu FJ, Bast RC, Yu YH. Ras-related NOE Y2 is a novel negative regulator of T cell signaling. Proceeding of the 89th Annual Meeting of the American Association for Cancer Research 39:534, 1998.
13. Lu Y, Gibson S, Khan H, Cuevas B, LaPushin R, Mills GB. ITK/EMT forms a tertiary complex with PI3K and CD28. Proceedings of the 88th Annual Meeting of the American Association for Cancer Research 38:64, 1997.
14. Lu Y, Trevillyan JM, Bjorndahl JM, Phillips CA. Phorbol ester treatment increases IL-2 production but decreases CD28-dependent cellular cytotoxicity. The FASEB Journal 10:A1450, 1996.
15. Trevillyan JM, Lu Y, Rodriguez RR, Phillips CA. Phosphatidylinositol 3-kinase activity is required for CD28-dependent cellular cytotoxicity. Proceedings of the 9th International Congress of Immunology, 1995.
16. Lu Y, Bjorndahl JM, Phillips CA, Trevillyan JM. Oligomerization of the CD28 receptor on human T-lymphocytes induces the association and tyrosyl phosphorylation of phosphatidylinositol 3-kinase. The FASEB Journal 8:A781, 1994.
17. Lu Y, Rodriguez RR, Bjorndahl JM, Trevillyan JM, Phillips CA. Phosphatidylinositol 3-kinase activity is essential for human natural killer (NK) cell antibody-dependent cellular cytotoxicity (ADCC). J. Leukocyte Biology, Supplement:Abst 8, 1994.
18. Trevillyan JM, Lu Y, Phillips CA. Phosphatidylinositol 3-kinase activity is not essential for CD28 costimulatory activity: Studies with a selective inhibitor, wortmannin. J Leukocyte Biology, Supplement:Abst LB45, 1994.
19. Bjorndahl JM, Lu Y, Trevillyan JM. Activation of a protein-tyrosine kinase pathway is required for CD69 signal transduction. J. Immunology 150:186A, 1993.
20. Lu Y, Bjorndahl JM, Phillips CA, Trevillyan JM. CD28-induced early signal transduction events require p56lck. J. Immunology 150:186A, 1993.
21. Dombrowski KE, Trevillyan JM, Cone JC, Lu Y, Phillips CA. Identification of an EctoATPase expressed by the human natural killer cell line NK3.3.: Possible role in cell mediated cytotoxicity. J. Immunology 150:208A, 1993.
22. Lu Y, Ganelli-Piperno A, Bjorndahl JM, Phillips CA, Trevillyan JM. CD28 induced T-cell activation: Evidence for a protein-tyrosine kinase signal transduction pathway. The FASEB Journal 6(4):1224, 1992.
23. Trevillyan JM, Lu Y, Phillips CA. CA T-lymphocyte activation. Panhandle Health 3:10-11, 1992.
24. Cone JC, Lu Y, Bjorndahl JM, Nuwayhid N, Trevillyan JM, Phillips CA. Signal transduction requirement of the Fc RIII/CD16 in the continuous NK cell line, NK3.3. Proceedings of the 8th International Natural Killer Cell Workshop and the 1st Meeting of the Society for Natural Immunity: Molecular and Cellular Aspects of Natural Killer Cell Triggering and Signaling, 1992.
25. Bjorndahl JM, Lu Y, Trevillyan JM. Signal transduction via CD69 requires the activation of a PTK pathway. Proceedings of the Texas Immunology Conference, 1992.
26. Courtney A, Wright SE, Lu Y, Trevillyan JM. Insect cell expression of lymphocyte protein-tyrosine kinase (p56lck) using baculovirus vector. Proceedings of the 67th Annual Meeting of the American Association for the Advancement of Science, Southwestern and Rocky Mountain Division, 1991.
27. Cone JC, Lu Y, Trevillyan JM, Phillips CA. FcyRIII and protein tyrosine kinase signal transduction in a continuous human NK cell line. Proceedings of the 28th National Meeting of the Society for Leukocyte Biology, 1991.
28. Trevillyan JM, Lu Y, Bjorndahl JM, Phillips CA. T-cell activation via CD28 pathway is blocked by a selective protein-tyrosine kinase inhibitor. The FASEB Journal 4(7):P.A2200, 1990.
29. Trevillyan JM, Bjorndahl JM, Lu Y, Atluru R. Inhibition of T-lymphocyte activation by a selective inhibitor of protein-tyrosine kinase. Blood 74:225a, 1989.
30. Lu Y, Ma A. Separation and identification of T and B lymphocytes from murine spleen. Selection of Abstracts 1979-1982, 1982. Shanghai Institute of Immunology:35, 1982.

Book Chapters

1. Smith DL, Nolden LK, Mills GB, Lu Y. Chemo- and Radiosensitization Through Inhibition of PI3K/Akt Signaling. (Invited). In: Cancer Drug Discovery and Development Apoptosis, Senescence and Cancer. The Human Press: New Jersey, 313-334, 2007.
2. Kohn EC, Lu Y, Wang H, Yu Q, Yu S, Hall H, Smith DL, Nolden L, Hortobagyi G, Mills GB. Targeted Therapeutics in Breast Cancer: Challenges to Success. In: Diseases of The Breast. 3rd. Lippincott Williams and Wilkins, 397-413, 2004.
3. Lu Y, Shayestri L, Lapushin R, Yu S, Cuevas B, Fang X, Eder A, Furui T, Plikoff D, Kuo WL, Baldocchi R, Vanhaesebroeck B, Bast RC, Pinkel D, Siminovitch K, Jaffe R, Gray J, Mills GB. Phosphatidylinositol 3 kinase as a Target in Selected Ovarian Cancers: From Genomics to Therapeutics. In: Ovarian Cancer, 413-422, 2002.
4. Gray JW, Collins C, Pinkel D, Shayesteh L, Lu Y, Mills GB. Genome scanning and gene discovery in breast and ovarian cancer. In: Proceedings of the 9th Pezcoller Foundation Symposium on the Biology of Tumors, 65-72, 1998.